Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2022

View Archived Issues

GPR30 is a therapeutic target in triple-negative inflammatory breast cancer

Small molecule inhibitors of natural killer group 2D identified at Janssen

Jazz and Werewolf announce global license and collaboration agreement to develop WTX-613

PX-478 prevents rise of glycemia and improves beta-cell function in models diabetes

Researchers in China find evidence in mice that bacteria in tumors help cancer cells metastasize

Novel HlyU inhibitor VM-17 attenuates the virulence of V. vulnificus

1st Bio Therapeutics presents new protein kinase inhibitors

Elastrin Therapeutics closes funding round to advance development of lead candidate

Seoul Techno Holdings identifies new compounds for cancer

Cadila Healthcare discloses new ACP1 inhibitors

Medshine Discovery patents AKR1C3 inhibitors

Soltego discloses new SIK inhibitors

New Fgf1a murine models of heart failure and metabolic syndrome developed

GPR171 agonism ameliorates chronic neuropathic and inflammatory pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...